1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Clearside Biomedical Signs Agreement with Santen Pharmaceutical for Eye Disease Treatment

12 Nov 2024
Admin
News Article

Clearside Biomedical Signs Agreement with Santen Pharmaceutical for Eye Disease Treatment

Overview

Clearside Biomedical announced a collaboration agreement between its Asia-Pacific partner, Arctic Vision, and Santen Pharmaceutical.

Clearside's Proprietary SCS® Injection

Clearside's proprietary SCS® injection approach delivers medication to the back of the eye, a location crucial for treating sight-threatening diseases.
The SCS Microinjector®, a patented device, injects a wide range of medications into the targeted area, potentially improving treatment effectiveness and reducing side effects.

About the UME

UME is a fluid build-up in the macula (responsible for central vision) caused by uveitis, an inflammatory eye condition.
It's a leading cause of vision loss, affecting millions globally.
Agreement between Arctic Vision & Santen
This agreement between Arctic Vision and Santen has the potential to bring ARVN001 to UME patients in Asia-Pacific, offering a new treatment option.
The agreement focuses on ARVN001 (XIPERE® in the US), a treatment for uveitic macular edema (UME) and other eye conditions under development.
Arctic Vision gains rights to commercialise ARVN001 in mainland China (excluding Taiwan, Hong Kong and Macau).

This deal strengthens Clearside's suprachoroidal delivery platform, already utilised by major pharmaceutical companies such as Bausch + Lomb, AbbVie and Santen.